ADVANCED SOLID TUMORS

This early-stage study tested the safety of an experimental drug called KL340399 when injected directly into tumors. The trial involved 6 patients with advanced solid cancers who had exhausted standard treatment options. Researchers aimed to find the highest safe dose and gather …

This study tested the safety and early effectiveness of an experimental drug called SHR-A1811 in people with advanced solid tumors that have a specific marker called HER2. The trial involved 396 participants whose cancer had progressed despite standard treatments. Researchers mon…

This early-stage study tested a new drug called MK-1200 in people with advanced cancers of the stomach, esophagus, bile ducts, or pancreas who had already tried all other treatments that could help them. The main goals were to find a safe dose and see if the drug could shrink tum…

This early-stage study aimed to find a safe dose for a new cancer drug called BMS-986408. It tested the drug alone and combined with other approved cancer immunotherapies in 68 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was…

This first-in-human study tested a new drug called KL340399 injection in 21 patients with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose, see how the body processes the drug, and check for any early signs that it …

This was the first study in humans to test a new cancer drug called AMG 305. It aimed to find a safe dose and see how the body processes the drug in 37 adults with advanced solid tumors who had run out of standard treatment options. The main goal was to check for side effects and…

This early-stage study tested a new experimental drug called BAT8006 in 216 patients with advanced solid tumors that had stopped responding to standard treatments. The main goal was to determine if the drug was safe and to find the highest dose patients could tolerate without sev…

This study allowed patients with various cancers who had benefited from the drug tazemetostat in earlier trials to continue receiving it. The main goal was to monitor the drug's long-term safety in these patients. It was open to people who had not seen their cancer worsen and cou…

This small, early-stage study tested a new type of personalized immune cell therapy called ALPP CAR-T in adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to see if the treatment was safe and if it could shrink tumors. Resea…

This early-stage study tested a new drug called IBI334 in adults with advanced solid tumors that could not be removed by surgery. The main goals were to check the drug's safety, see how much patients could tolerate, and gather initial signs of whether it could shrink or control t…

This was an early-stage safety study for a new cancer drug called AMG 256. It involved 34 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose for future testing and to understand how the body processes the …

This early-stage trial tested a new oral medication called ASC61 in 18 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find the safest dose, see how the body processes the drug, and look for early signs that it might he…

This study aimed to find the best length of immunotherapy treatment for people with advanced cancers. It enrolled 161 patients whose cancer had remained stable after one year of treatment. Researchers randomly assigned participants to either stop their immunotherapy or continue i…

This early-stage study tested a new cancer drug called RO7623066, both alone and combined with other treatments, in 116 patients with advanced solid tumors. The main goals were to find the safest dose and see how the body processes the drug. Researchers also looked for early sign…

This early-stage study tested a new oral drug called BAY2862789 in 45 people with advanced solid tumors that had stopped responding to standard treatments. The drug works by activating the body's own immune T-cells to fight cancer. Researchers primarily wanted to determine safe d…

This first-in-human study tested a new drug called ABBV-155, both alone and combined with standard chemotherapy, in adults with advanced solid tumors that had returned or stopped responding to prior treatments. The main goals were to find safe doses and see if the drug showed ear…

This trial tested a new two-step treatment for people with advanced solid tumors that had stopped responding to standard therapies. First, doctors used heat to destroy a tumor. Then, they injected a substance called IP-001 into the same area, hoping to 'teach' the body's immune s…

This was the first study in humans to test a new drug called ZGGS15 for people with advanced solid tumors that have stopped responding to standard treatments. The main goals were to check the drug's safety, see what side effects occur, and find the highest dose patients can toler…

This study tested a new combination of two immunotherapy drugs (relatlimab and nivolumab) in Chinese patients with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the safety of the drugs in the body and see early signs of whe…

This study tested the safety and effectiveness of combining two drugs, pembrolizumab and lenvatinib, in people with advanced solid tumors that had stopped responding to standard treatments. It involved 611 participants with cancers like triple-negative breast, ovarian, gastric, c…

This was a first-in-human study to test the safety and find the right dose of a new drug called BAT6026 for patients with advanced solid tumors. It involved 30 adults whose cancer had progressed despite standard treatments. The main goal was to see how much of the drug patients c…

This study aimed to understand how a common antifungal drug (itraconazole) affects the body's processing of a cancer medication (lurbinectedin). It involved 14 patients with advanced solid tumors who received both drugs in different sequences. The main goal was to measure drug le…